Management of Stage T3 Clear Cell Renal Cell Carcinoma

Surgical Management

Open radical nephrectomy remains the standard of care for locally advanced RCC (T3 and T4), although a laparoscopic approach can be considered in select cases 1
The goal of surgery should be to obtain negative margins to maximize oncological outcomes 2
Systematic adrenalectomy is not recommended when abdominal CT shows no evidence of adrenal invasion 1, 2
Extensive lymph node dissection is not routinely recommended unless there is clinical evidence of lymph node involvement 1, 2
For tumors with venous thrombus (common in T3 disease), surgical intervention to remove the thrombus should be considered, though the approach depends on thrombus level 1

T3 clear cell RCC is considered high risk with a 5-year metastasis-free survival of approximately 31.2% for patients with a SSIGN score ≥6 3
Risk factors that should be assessed include nuclear grade (grade 3-4 increases risk) 3
Tumor size (≥10 cm increases risk) 3
Histological tumor necrosis 3

Currently, there is no universally recommended adjuvant treatment following surgery, though several clinical trials have investigated this approach 1
The S-TRAC trial showed improved disease-free survival with adjuvant sunitinib, but without overall survival benefit 1
The European Medicines Agency (EMA) has not approved adjuvant therapy with VEGFR-targeted agents due to the imbalance between risk and clinical benefit 1
Inclusion of patients into clinical trials should be encouraged 3

Neoadjuvant approaches are still experimental and should not be proposed outside of clinical trials 1, 3
Attempting to downsize venous tumor thrombi with systemic targeted therapy before surgery is not recommended 1

If metastatic disease is present at diagnosis, cytoreductive nephrectomy may still be considered in patients with good performance status and limited volume of metastatic disease 2, 5
For patients with venous tumor thrombus, the surgical approach should be tailored based on the extent of the thrombus 1
Patients with T3 disease should be considered for enrollment in adjuvant therapy clinical trials when available 3